Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
SpringWorks Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SWTX
Nasdaq
8731
https://www.springworkstx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for SpringWorks Therapeutics Inc
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
- Mar 4th, 2024 11:30 am
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
- Feb 29th, 2024 1:30 pm
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
- Feb 27th, 2024 12:12 pm
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
- Feb 27th, 2024 11:30 am
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
- Feb 22nd, 2024 12:00 pm
SpringWorks Therapeutics Inc Insider Sells Company Shares
- Feb 7th, 2024 7:42 am
SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
- Feb 6th, 2024 4:26 am
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Jan 31st, 2024 12:00 pm
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2024 11:30 am
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2023 12:00 pm
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Dec 8th, 2023 9:05 pm
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Dec 5th, 2023 5:32 am
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
- Dec 4th, 2023 9:13 pm
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Nov 29th, 2023 12:00 pm
SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment
- Nov 28th, 2023 9:03 pm
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
- Nov 27th, 2023 11:04 pm
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
- Nov 16th, 2023 11:30 am
SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial Results
- Nov 2nd, 2023 11:54 am
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 2nd, 2023 10:30 am
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
- Nov 1st, 2023 10:30 am
Scroll